Resumen:
Cold Atmospheric Plasma (CAP) and Plasma Activated Media (PAM) are effective against bacteria, fungi, cancer cells, and viruses because they can deliver Reactive Oxygen and Nitrogen Species (RONS) on a living tissue with negligible damage on health cells. The antiviral activity of CAP against SARS-CoV-2 is being investigated, however, the same but of PAM has not been explored despite its potential. In the present study, the capability of Plasma Activated Media (PAM) to inactivate SARS-CoV-2 and PR8 H1N1 influenza virus with negligible damage on healthy cells is demonstrated. PAM acted by both virus detaching and diminished replication. Furthermore, the treatment of A549 lung cells at different times with buffered PAM did not induce interleukin 8 expression, showing that PAM did not induce inflammation. These results open a new research field by using PAM to the development novel treatments for COVID-19, influenza, and other respiratory diseases.
Resumen divulgativo:
Se abre un campo de investigación para el tratamiento de la COVID-19 y la gripe y para el control de la propagación de virus respiratorios. Investigadores españoles demuestran la vulnerabilidad de los virus SARS-CoV-2 y PR8 H1N1 a los medios activados con plasma atmosférico. Sci Rep 12, 263 (2022)
Palabras Clave: Plasma Medicine, Plasma Activated Media, Covid-19
Índice de impacto JCR y cuartil WoS: 4,600 - Q2 (2022); 3,800 - Q1 (2023)
Referencia DOI:
https://doi.org/10.1038/s41598-021-04360-y
Publicado en papel: Diciembre 2022.
Publicado on-line: Enero 2022.
Cita:
O.D. Cortázar, A. Megia-Macías, S. Moreno Fernández, A. Brun Torres, E. Gómez-Casado, Vulnerability of SARS-CoV-2 and PR8 H1N1 virus to cold atmospheric plasma activated media. Scientific Reports. Vol. 12, pp. 263-1 - 263-12, Diciembre 2022. [Online: Enero 2022]
Descargar el artículo